Full-Time
Director of Value Creation
Updated on 9/10/2026
Becton Dickinson
10,001+ employees
Global medical devices and diagnostics provider
Compensation Overview
$183.7k - $293.9k/yr
San Diego, CA, USA
Remote
Travel up to 65% is required.
Bachelor's, Master's, MBA, PharmD
 Business & Strategy (1) |
|---|
Get referred to Becton Dickinson
See people who can refer or advise you
- A bachelor's degree is required.
- At least 7 years of experience in healthcare operations or management, provider transformation, MedTech solution development, or value engineering is required.
- Experience with financial and deal modeling, contract structures, and solution architecture is required.
- Knowledge of Lean, Six Sigma, DMAIC, and change management methodologies is required.
- Established people management experience, including oversight of team performance and development, coaching, and mentoring, is required.
- Strong leadership skills and the ability to drive organizational change are required.
- Exceptional executive communication, presentation, and consultative selling capabilities are required.
- Ability to build relationships and communicate across organizational levels and with customers in a matrixed environment is required.
- Ability to balance hands-on execution with strategic thinking, drive progress, manage competing priorities, and work independently is required.
- Strong problem-solving, organizational, analytical, and critical-thinking abilities are required.
- Strong follow-through and customer service skills are required.
- Strong organizational, project-planning, and scheduling skills are required.
- Proficiency with Microsoft Office tools, including Email, Word, Excel, PowerPoint, Teams, and SharePoint, is required.
- Ability to travel up to 65% is required.
- Ability to ensure quality, privacy, and compliance with HIPAA and protected health information requirements is required.
- Own end-to-end pre-deal value strategy for integrated delivery network opportunities, including scoping, planning, hypothesis-led assessments, data requests, baselines, and impact sizing across clinical, operational, and financial domains.
- Architect solutions using standardized commercial constructs, key performance indicator and measurement frameworks, guardrails, risk language, and post-deal implementation and economic considerations across BD MMS platforms.
- Lead deal architecture by developing and standardizing contract frameworks and pricing constructs aligned with operational capacity and risk tolerance.
- Build and own financial deal models connecting revenue, margin, capacity and ramp, and outcomes exposure through sensitivity and scenario analysis aligned with Finance and Delivery.
- Steward BD MMS's multi-year capital plan and align capital sequencing with account strategies, return on investment, payback, and portfolio risk.
- Partner with Sales and Value Engineering to shape, accelerate, and scale opportunities through executive storylines, value hypotheses, stakeholder mapping, objection handling, and commercialization plans.
- Engage provider chief executive, financial, operating, nursing, and pharmacy executives to align on value, feasibility, risk, change readiness, and governance.
- Collaborate with Finance, Legal and Contracting, Clinical, Supply Chain, Product, Value Engineering and PMO, and Insights teams to ensure feasible, risk-balanced solutions and shorten cycle time.
- Build and mature the practice through an operating model, standard work, playbooks, performance dashboards, intake templates, data dictionaries, and benefits-validation methods.
- Continuously improve pricing, packaging, contract standards, and measurement methods through closed-loop learning, delivery outcomes, and win/loss reviews.
- Recruit, onboard, and develop the Value Creation team; establish career paths, coaching rhythms, and utilization targets.
- Ensure quality, privacy, compliance, and MedTech quality expectations throughout the pursuit process.
- An advanced degree such as PharmD, MSN/RN, MBA, MHA, or MS is preferred.
- A consulting background is desirable.
- A clinical background in Pharmacy or Nursing is strongly preferred; Healthcare Management experience is acceptable.
BD is a global medical technology company serving hospitals, labs, and healthcare providers with products across BD Medical, Life Sciences, and Interventional. Its offerings include medication management and delivery devices, safe specimen collection and transport systems, and minimally invasive surgical instruments. Its products help safe medication administration, preserve specimen integrity for diagnostics, and enable less-invasive procedures, saving time and improving outcomes. BD differentiates itself with a broad end-to-end portfolio, global reach, and focus on quality, safety, and service to support care across regions; its goal is to improve patient outcomes, lower costs, and increase efficiency in care environments.
Company Size
10,001+
Company Stage
IPO
Headquarters
Franklin Lakes, New Jersey
Founded
1961
Get referred to Becton Dickinson
See people who can refer or advise you
Simplify's Take
What believers are saying
- BD’s August 6, 2026 quarter delivered $5.0 billion revenue and $3.23 adjusted EPS.
- Management raised 2026 guidance after foreign-exchange-neutral growth beat expectations in Q3.
- Phasix enrollment finished August 13, 2026, strengthening BD’s hernia-prevention expansion path.
What critics are saying
- FDA classified BD’s intraosseous recall Class I on August 17, 2026.
- The recall lists four deaths, 45 serious injuries, and 75 complaints through July 22, 2026.
- Bard mesh litigation still haunts BD; another quality failure could trigger enterprise-wide trust collapse.
What makes Becton Dickinson unique
- BD’s February 9, 2026 Waters spin-off left a pure-play medtech portfolio.
- BD’s Vystra pen platform anchors GLP-1 and biologic delivery partnerships like EMS Brazil.
- BD’s interventional and surgery franchises sell mission-critical devices into hospital emergency workflows.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
401(k) Retirement Plan
Tuition Reimbursement
Growth & Insights and Company News
6 month growth
↑ 9%1 year growth
↑ 9%2 year growth
↑ 9%Becton, Dickinson and Company shares have gained 19.6% over the past year, slightly trailing the S&P 500's 20.4% rise. However, in 2026 year-to-date, the stock has outperformed with a 20.2% gain versus the index's 13.7% advance. The medical technology company, valued at $50.5 billion by market cap, manufactures medical supplies, devices, laboratory equipment, and diagnostic products. It has outpaced the iShares U.S. Medical Devices ETF, which declined 9.5% over the past year. BDX's shares rose 3.8% on 6 August after reporting third-quarter results. Adjusted earnings per share of $3.23 exceeded analyst expectations of $3.14, whilst revenue of $5 billion surpassed the $4.9 billion forecast. Among 16 analysts covering the stock, the consensus rating is "Moderate Buy", comprising seven "Strong Buy" ratings and nine "Holds".
BD has appointed Gary Sorsher as executive vice president and chief quality officer, effective 8 September. Sorsher brings over 30 years of experience in quality leadership at medical technology companies, most recently serving as chief quality officer at Edwards Lifesciences. The appointment follows the announcement that Jeffrey Silvestri, senior vice president and global head of quality, will retire in October after more than 25 years with BD. Silvestri joined the company in 1998 and has been instrumental in strengthening BD's quality foundation. Tom Polen, BD's chairman, CEO and president, emphasised that quality is central to earning trust with customers and patients. He expressed confidence in Sorsher's ability to advance quality excellence across the organisation.
BD fully enrolls trial of resorbable mesh for hernia prevention. BD called completing enrollment in the study "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Published Aug. 13, 2026 Dive brief: * BD said Wednesday it has completed enrollment in a clinical trial of resorbable mesh for preventing incisional hernias after open abdominal surgery. * Investigators enrolled 477 patients across 32 sites in the U.S. and Europe to compare the effect of BD's Phasix mesh and primary suture closure on the rate of incisional hernias. * BD will follow patients through the trial's primary endpoint at 24 months, beyond which it expects to use the data to seek Food and Drug Administration authorization for the indication. Dive insight: Incisional hernia is a serious and relatively common postoperative complication of elective abdominal surgeries where a large incision is made through the abdominal wall. BD's Phasix is a resorbable mesh. CR Bard, which BD bought for $24 billion in 2017, received FDA clearance in 2015 for Phasix in settings including hernia repair. Later, long-term data on the device confirmed the absence of mesh complications such as pain and infection. BD has faced lawsuits over adverse events allegedly linked to Bard meshes made from other materials. By completing enrollment in its PREVENT trial, BD took a step toward expanding the Phasix label to cover the prophylactic use of the device in patients undergoing elective open midline laparotomy surgery. Evaluating Phasix in hernia prevention builds on "decades of innovation in abdominal wall surgery" and will generate evidence that could "help broaden the role of regenerative technologies for patients at risk of post-surgical complications," Rian Seger, worldwide president of surgery at BD, said in a statement. BD called completion of enrollment in the clinical trial "a significant milestone in its advanced tissue regeneration strategy and expansion efforts." Last week, the company reported double-digit growth in sales of its infection prevention and advanced tissue regeneration products in the third quarter of its financial year. Discussing tissue regeneration on BD's third-quarter earnings call, CEO Thomas Polen said the company expects "strong growth going forward." Polen supported the expectations by highlighting clinical trials that the company is running to bring its biomaterial "into new indications to continue to expand our presence in those spaces."
Becton Dickinson reported third-quarter fiscal 2026 sales of $4,983 million, whilst net income fell to $377 million. The medical technology company modestly raised its full-year outlook for low single-digit revenue growth. BD highlighted momentum in biologic drug delivery and GLP-1 partnerships, including a new semaglutide pen collaboration with EMS in Brazil. The company's Vystra Injection Pen platform is gaining traction in chronic disease treatment. FX-neutral revenue grew faster than expected, leading management to nudge guidance higher. However, the sharp drop in year-to-date net income and recent one-off loss raise questions about earnings quality. The company maintained its $4.20 annual dividend. Shares rose 6.8% following the results, though some analysts suggest the stock remains undervalued by approximately 25%.
BD reported third quarter fiscal 2026 revenue of $5.0 billion, up 5.4% as reported and 4.4% on a foreign exchange-neutral basis. GAAP diluted earnings per share from continuing operations reached $1.64, whilst adjusted diluted EPS came in at $3.23. Year-to-date cash from continuing operations increased 33.3% to $2.1 billion. Free cash flow rose 44.6% to $1.7 billion. The medical technology company updated its full-year guidance, expecting revenue growth towards the high end of its range whilst raising the midpoint of its adjusted diluted EPS guidance. The results represent BD's first full quarter following the 9 February 2026 spin-off of its Biosciences and Diagnostic Solutions business and its combination with Waters Corporation.